Denali Therapeutics Inc (NASDAQ:DNLI) Receives $27.83 Consensus PT from Brokerages

Denali Therapeutics Inc (NASDAQ:DNLI) has been given a consensus rating of “Buy” by the ten research firms that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $27.83.

Several research firms have commented on DNLI. TheStreet lowered shares of Denali Therapeutics from a “c-” rating to a “d” rating in a research note on Thursday, June 13th. Zacks Investment Research upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 27th. Nomura began coverage on shares of Denali Therapeutics in a research note on Friday, September 13th. They issued a “buy” rating and a $35.00 price objective for the company. HC Wainwright reiterated a “buy” rating on shares of Denali Therapeutics in a research note on Thursday, August 8th. Finally, Wedbush began coverage on shares of Denali Therapeutics in a research note on Wednesday, September 25th. They issued a “neutral” rating and a $19.00 price objective for the company. They noted that the move was a valuation call.

Shares of DNLI traded up $0.24 on Friday, reaching $15.44. The company’s stock had a trading volume of 5,461 shares, compared to its average volume of 374,113. The company has a current ratio of 10.65, a quick ratio of 10.66 and a debt-to-equity ratio of 0.15. Denali Therapeutics has a twelve month low of $13.78 and a twelve month high of $28.86. The stock has a market capitalization of $1.46 billion, a PE ratio of -39.67 and a beta of 2.15. The firm has a fifty day moving average of $17.38 and a 200-day moving average of $20.51.



Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.15). The firm had revenue of $4.20 million during the quarter, compared to analysts’ expectations of $4.52 million. Denali Therapeutics had a negative net margin of 40.78% and a negative return on equity of 11.03%. As a group, equities analysts anticipate that Denali Therapeutics will post -2.07 EPS for the current fiscal year.

In other news, COO Alexander O. Schuth sold 7,500 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.16, for a total transaction of $136,200.00. Also, CEO Ryan J. Watts sold 8,581 shares of the stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $18.05, for a total transaction of $154,887.05. Following the transaction, the chief executive officer now directly owns 12,505 shares of the company’s stock, valued at $225,715.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,581 shares of company stock valued at $432,162. Company insiders own 21.20% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System boosted its holdings in Denali Therapeutics by 19.3% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 20,555 shares of the company’s stock worth $427,000 after buying an additional 3,330 shares during the period. Xact Kapitalforvaltning AB bought a new position in Denali Therapeutics in the 2nd quarter worth approximately $210,000. Baillie Gifford & Co. boosted its holdings in Denali Therapeutics by 18.3% in the 2nd quarter. Baillie Gifford & Co. now owns 7,407,229 shares of the company’s stock worth $153,773,000 after buying an additional 1,145,003 shares during the period. Acadian Asset Management LLC boosted its holdings in Denali Therapeutics by 136.7% in the 2nd quarter. Acadian Asset Management LLC now owns 11,650 shares of the company’s stock worth $241,000 after buying an additional 6,728 shares during the period. Finally, Chicago Equity Partners LLC bought a new position in Denali Therapeutics in the 2nd quarter worth approximately $2,438,000. 73.91% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

See Also: What are the risks of holding treasury bonds?

Analyst Recommendations for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.